Drug Profile
Research programme: integrin signal transducers - Millennium/Scripps
Alternative Names: Integrin signal transducers research programme - Millennium/ScrippsLatest Information Update: 24 Aug 2007
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals; The Scripps Research Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Thrombosis
Most Recent Events
- 21 Mar 2002 COR Therapeutics has been acquired by, and integrated into, Millennium Pharmaceuticals
- 20 Jul 2000 New profile
- 20 Jul 2000 Preclinical development for Atherosclerosis in USA (Unknown route)